Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure

Cardiovasc Diabetol

28 Aprile Apr 2022 24 days ago
  • Rurali E, Perrucci GL, Raucci A, Pompilio G, Genovese S, Vinci MC

Glucagon like peptide-1 receptor agonists (GLP-1RAs) have shown to reduce mortality and cardiovascular events in patients with type 2 diabetes mellitus (T2DM). Since the impairment in number and function of vasculotrophic circulating CD34+ hematopoietic stem progenitor cells (HSPCs) in T2D has been reported to increase cardiovascular (CV) risk, we hypothesized that one of the mechanisms whereby GLP-1 RAs exert CV protective effects may be related to the ability to improve CD34+ HSPC function.

Reference: Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure. Sforza A, Vigorelli V, Rurali E, Perrucci GL, Gambini E, Arici M, Metallo A, Rinaldi R, Fiorina P, Barbuti A, Raucci A, Sacco E, Rocchetti M, Pompilio G, Genovese S, Vinci MC. Cardiovasc Diabetol. 2022 Apr 9;21(1):51.

Go to PubMed